Monosomal and complex karyotypes as prognostic parameters in patients with International Prognostic Scoring System higher risk myelodysplastic syndrome treated with azacitidine

Blood Research

Volumn 49, Issue 4, 2014, Pages 234-240

  Hwang, Kyung Lim ^a   Song, Moo Kon ^a   Shin, Ho Jin ^a   Na, Hae Jung ^a   Shin, Dong Hun ^a   Kim, Joong Keun ^a   Moon, Joon Ho ^b   Ahn, Jae Sook ^c   Song, Ik Chan ^d   Hong, Junshik ^e   Lee, Gyeong Won ^f   Chung, Joo Seop ^a  

^a Pusan National University School of Medicine   (South Korea)

^b Kyungpook National University Hospital   (South Korea)

^c Chonnam National University Research Institute of Medical Sciences   (South Korea)

^d Chungnam National University   (South Korea)

^e Gachon University   (South Korea)

^f Gyeongsang National University   (South Korea)

Author keywords

Azacitidine; Chromosomal abnormalities; Complex karyotype; Monosomal karyotype; Myelodysplastic syndrome

Indexed keywords

AZACITIDINE; HYDROXYUREA;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER SURVIVOR; CHROMOSOME 5; CHROMOSOME 7; CHROMOSOME ABERRATION; COMPLEX KARYOTYPE; CONTROLLED STUDY; CYTOGENETICS; DRUG DOSE REDUCTION; FEMALE; FOLLOW UP; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MONOSOMAL KARYOTYPE; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE NEOPLASM; OUTCOME ASSESSMENT; OVERALL SURVIVAL; RETROSPECTIVE STUDY; SEX RATIO; THERAPY DELAY; TREATMENT DURATION;

EID: 84920995801     PISSN: 2287979X     EISSN: 22880011     Source Type: Journal    
DOI: 10.5045/br.2014.49.4.234     Document Type: Article

References (24)

1. Tefferi A, Vardiman JW. Myelodysplastic syndromes. N Engl J Med 2009;361:1872-85.
2. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-88.
3. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002;20:2429-40.
4. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010;28:562-9.
5. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009;10: 223-32.
6. Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007;25: 3503-10.
7. Haase D, Germing U, Schanz J, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 2007;110:4385-95.
8. Schanz J, Steidl C, Fonatsch C, et al. Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system. J Clin Oncol 2011;29:1963-70.
9. Breems DA, Van Putten WL, De Greef GE, et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol 2008;26:4791-7.
10. Patnaik MM, Hanson CA, Hodnefield JM, Knudson R, Van Dyke DL, Tefferi A. Monosomal karyotype in myelodysplastic syndromes, with or without monosomy 7 or 5, is prognostically worse than an otherwise complex karyotype. Leukemia 2011; 25:266-70.
11. Belli CB, Bengio R, Aranguren PN, et al. Partial and total monosomal karyotypes in myelodysplastic syndromes: comparative prognostic relevance among 421 patients. Am J Hematol 2011;86:540-5.
12. Itzykson R, Thepot S, Eclache V, et al. Prognostic significance of monosomal karyotype in higher risk myelodysplastic syndrome treated with azacitidine. Leukemia 2011;25:1207-9.
13. Shaffer LG, McGowan-Jordan J, Schmid M. ISCN 2013. An international system for human cytogenetic nomenclature. Recommendations of the International Standing Committee on Human Cytogenetic Nomenclature. Basel, Switzerland: Karger, 2013.
14. Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006;108:419-25.
15. Wijermans PW, Lubbert M, Verhoef G, Klimek V, Bosly A. An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2'-deoxycytidine (decitabine) in 177 patients. Ann Hematol 2005;84(Suppl 1):9-17.
16. Kantarjian HM, O'Brien S, Shan J, et al. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Cancer 2007;109: 265-73.
17. Itzykson R, Thepot S, Quesnel B, et al. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood 2011;117:403-11.
18. Valcarcel D, Adema V, Sole F, et al. Complex, not monosomal, karyotype is the cytogenetic marker of poorest prognosis in patients with primary myelodysplastic syndrome. J Clin Oncol 2013;31:916-22.
19. Schanz J, Tuchler H, Sole F, et al. Monosomal karyotype in MDS: explaining the poor prognosis? Leukemia 2013;27:1988-95.
20. Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012;120:2454-65.
21. Bernasconi P, Boni M, Cavigliano PM, et al. Clinical relevance of cytogenetics in myelodysplastic syndromes. Ann N Y Acad Sci 2006;1089:395-410.
22. Boultwood J, Lewis S, Wainscoat JS. The 5q-syndrome. Blood 1994;84:3253-60.
23. Zou YS, Fink SR, Stockero KJ, et al. Efficacy of conventional cytogenetics and FISH for EGR1 to detect deletion 5q in hematological disorders and to assess response to treatment with Lenalidomide. Leuk Res 2007;31:1185-9.
24. Mallo M, Cervera J, Schanz J, et al. Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q. Leukemia 2011;25: 110-20.